Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Catalyst Pharmaceuticals, Inc. to Angelini Pharma S.p.A. for $31.50 per share in cash.Halper Sadeh encourages Catalyst ...

Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

CPRX's Q1 earnings are expected to beat estimates on strong Firdapse demand and rising Agamree sales, while Fycompa faces ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain ...

What Is Multi-Timeframe Analysis? How to Align Weekly, Daily, and Hourly Charts Shares of Catalyst Pharmaceuticals, Inc. (CPRX) up 148% since 2022’s first outlier institutional inflow signal. CPRX ...

Catalyst Pharmaceuticals soared 19% after a report that Italian drugmaker Angelini Pharma is evaluating a potential purchase ...

Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). But which of these two ...

Investors with an interest in Medical - Drugs stocks have likely encountered both Catalyst Pharmaceutical (CPRX) and Zoetis (ZTS). But which of these two stocks is more attractive to value investors?